drugset / Trial / NCT07076186

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

NCT07076186

Phase 2 Suspended 48 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To find out if receiving standard chemotherapy (doxorubicin and trabectedin) can extend the cancer-free survival of patients with Stage 1b/2 uterine leiomyosarcoma who had surgery that fully removed the tumor.

Timeline

Start
2025-10-02
Primary completion
2027-12-02
Completion
2029-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified Intravenous
Subject Trabectedin Small molecule Intravenous

Indications